Jim Palma is Chief Executive Officer of TargetCancer Foundation (TCF). Since joining TCF in 2010, Jim has overseen its growth from a small, Boston-based start-up to a nationally recognized foundation driving comprehensive rare cancer research programs and patient support services.
Jim is a member of the Board of Directors of the National Organization for Rare Disorders (NORD) and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim is a Steering Committee member at the Global Cholangiocarcinoma Alliance, and also serves as a member of the Programmatic Panel of the US Army Medical Research and Development Command Rare Cancers Research Program. Prior to joining TargetCancer Foundation, Jim spent eleven years at Fidelity Investments in Boston, MA. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland.